Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BEIGENE, LTD.

(BGNE)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-01 pm EST
254.28 USD   -0.67%
02/01BeiGene to Present at Upcoming Investor Conferences
BU
01/31Beigene, Ltd. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
01/24Morgan Stanley Adjusts Price Target on BeiGene to $325 From $295, Maintains Overweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about BEIGENE, LTD.
02/01BeiGene to Present at Upcoming Investor Conferences
BU
01/24Morgan Stanley Adjusts Price Target on BeiGene to $325 From $295, Maintains Overweight ..
MT
01/23Beigene : Announces Expansion of Coverage on China's National Reimbursement Drug List - Fo..
PU
01/20Asian Equities Rally in Friday Trading as ADRs Set to Close Week 2% Higher
MT
01/20Guggenheim Raises Price Target on BeiGene to $350 From $290, Maintains Buy Rating
MT
01/20SVB Securities Adjusts Price Target on BeiGene to $300 From $236, Maintains Outperform ..
MT
01/20Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phas..
AQ
01/20BRUKINSA Receives Marketing Authorization for Chronic Lymphocytic Leukemia and Marginal..
AQ
01/19US FDA Approves BeiGene's Lymphocytic Leukemia Treatment
MT
01/19BeiGene's Brukinsa Secures US FDA Approval for Chronic Lymphocytic Leukemia
MT
01/19BRUKINSA« Approved in the U.S. for Chronic Lymphocytic Leukemia
BU
01/19BeiGene Announces BRUKINSA Approved in the U.S. for Chronic Lymphocytic Leukemia
CI
01/19BeiGene Announces Expansion of Coverage on China's National Reimbursement Drug List
AQ
01/19BeiGene Says Brukinsa Gets UK Marketing Authorization for Chronic Lymphocytic Leukemia,..
MT
01/19BRUKINSA« (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leuke..
BU
01/19Brukinsa (Zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukem..
CI
01/19Four New Indications for BeiGene's Tislelizumab Included in China's Expanded National R..
MT
01/18BeiGene Says China National Reimbursement Drug List Expanded Coverage of its Drugs
MT
01/18BeiGene Announces Expansion of Coverage on China's National Reimbursement Drug List
BU
01/18BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug Lis..
CI
01/17Insider Sell: Beigene
MT
01/17BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO..
BU
01/17Leap Therapeutics Acquires Flame Biosciences
AQ
01/12Insider Sell: Beigene
MT
01/11Insider Sell: Beigene
MT
01/09Transcript : BeiGene, Ltd. Presents at 41st Annual J.P. Morgan Healthcare Con..
CI
01/05Beigene : Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor T..
PU
01/05BeiGene, Ltd. Announces Center for Drug Evaluation of the China National Medical Produc..
CI
01/04BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
BU
01/01Chinese Regulator Accepts BeiGene's Biologics License Application for Hepatocellular Ca..
MT
2022BeiGene Says Chinese Regulator Accepts Application for Tislelizumab to Treat Liver Canc..
MT
2022BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor ..
BU
2022BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor ..
CI
2022Asian Equities Follow US Market Sell-Off, Move Sharply Lower Thursday
MT
2022Jazz Pharmaceuticals And Zymeworks Announce Jazz Has Confirmed Opt-In And Advances Part..
AQ
2022BeiGene, Ltd.(SHSE:688235) added to Shanghai Stock Exchange Composite..
CI
2022BeiGene, Ltd.(SHSE:688235) added to Shanghai Stock Exchange A Share I..
CI
2022Immix Biopharma Doses 16th Patient in Phase 1b/2a IMX-110 Monotherapy Trial
MT
2022Zymeworks Announces Positive Topline Data in The Pivotal HERIZON-BTC-01 Trial Of Zanida..
AQ
2022Indian Morning Briefing: Asian Markets Track Wall Street Lower
DJ
2022Certain Restricted Share Units of BeiGene, Ltd. are subject to a Lock-Up Agreement Endi..
CI
2022Certain Options of BeiGene, Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-20..
CI
2022Certain A Shares of BeiGene, Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-2..
CI
2022BeiGene's BRUKINSA Demonstrated Superior Progression-Free Survival Over IMBRUVICA in Ch..
AQ
2022BeiGene Lymphocytic Leukemia Treatment Shows Efficacy in Phase 3 Trial
MT
2022Transcript : BeiGene, Ltd. - Special Call
CI
2022BeiGene Says Final Phase 3 Study Data Show Brukinsa More Effective Than Imbruvica in Ch..
MT
2022áBeiGene's BRUKINSA« (zanubrutinib) Demonstrated Superior Progression-Free Survival Ove..
BU
2022Beigene, Ltd.'S Brukinsa Demonstrated Superior Progression-Free Survival over Imbruvica..
CI
2022Asian Equities Drop Sharply as COVID Infections Surge in China
MT
2022Zymeworks Inc - New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cance..
AQ
2022BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey ..
AQ
2022SVB Securities Adjusts BeiGene Price Target to $236 From $210, Maintains Outperform Rat..
MT
2022Transcript : BeiGene, Ltd. - Special Call
CI
2022BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey ..
BU
2022BeiGene, Phanes Therapeutics to Evaluate PT199-Tislelizumab Combo in Solid Tumor Trial
MT
2022Phanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 ..
PR
2022Asian Equities Decline Despite Reports China Will Further Ease COVID Restrictions
MT
2022BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for B..
AQ
2022BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for B..
BU
2022Beigene to Present Final Pfs Results from Alpine Trial Demonstrating Superior Pfs for B..
CI
2022Beigene, Ltd. Announces Change of Co-Chair of Scientific Advisory Committee
CI
2022BeiGene Receives European Commission Approval for BRUKINSA for the Treatment of Adults ..
AQ
2022European Commission Approves BeiGene's Chronic Lymphocytic Leukemia Treatment; Shares S..
MT
2022BeiGene's Brukinsa Drug Wins EU Nod For Chronic Lymphocytic Leukemia
MT
2022Insider Sell: Beigene
MT
2022Insider Sell: Beigene
MT
2022Sector Update: Health Care Stocks Decline Premarket Thursday
MT
2022BeiGene Says European Commission Approves Brukinsa as Treatment for Chronic Lymphocytic..
MT
2022BeiGene Receives European Commission Approval for BRUKINSA« (zanubrutinib) for the Trea..
BU
2022BeiGene Receives European Commission Approval for Brukinsa« (Zanubrutinib) for the Trea..
CI
2022BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental H..
BU
2022BeiGene's Brukinsa Secures Brazilian Approvals for Certain Cancers; Shares Rise
MT
2022SVB Securities Adjusts Price Target on BeiGene to $210 From $200, Maintains Outperform ..
MT
2022Nomura Adjusts BeiGene Price Target to $281.78 From $286.31, Maintains Buy Rating
MT
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on BEIGENE, LTD.